ArticleDisease markers2020
Association between Plasma Sestrin2 Levels and the Presence and Severity of Coronary Artery Disease.
Article in Disease markers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 19 citations in OpenAlex.
- Review
- SESN2 as a Novel Diagnostic and Prognostic Biomarker for Kawasaki Disease and Coronary Artery Lesions.Journal of inflammation research · 2026Article
- The association between plasma levels of Sestrin2 and risk factors of cardiovascular diseases in healthy and diabetic adults: A study of Qatar Biobank data.Biomolecules & biomedicine · 2025Article
- Novel Circulating Biomarkers in Aortic Valve Stenosis.International journal of molecular sciences · 2025Review
- Sestrin2 as a Protective Shield against Cardiovascular Disease.International journal of molecular sciences · 2023Review
- Sestrin2: multifaceted functions, molecular basis, and its implications in liver diseases.Cell death & disease · 2023Review
- Serum Sestrin2 Emerges as a Prognostic Biomarker of Human Aneurysmal Subarachnoid Hemorrhage: A Prospective Observational Cohort Single-Center Study.International journal of general medicine · 2023Article
- Sestrin2 in diabetes and diabetic complications.Frontiers in endocrinology · 2023Review
- The association between serum Sestrin2 and the risk of coronary heart disease in patients with type 2 diabetes mellitus.BMC cardiovascular disorders · 2022Article
- Inhibition of Sestrin2 overexpression in diabetic cardiomyopathy ameliorates cardiac injury via restoration of mitochondrial function.Experimental and therapeutic medicine · 2022Article
- Serum Sestrin2 Was Lower in Septic Shock Patients with Cardiomyopathy.Disease markers · 2022Article
- Oxidative Stress-Induced Protein of SESTRIN2 in Cardioprotection Effect.Disease markers · 2022Review
- Sestrin2 and Beclin1 levels in Polycystic Ovary Syndrome.Journal of clinical laboratory analysis · 2021Article
- The Protective Role of Sestrin2 in Atherosclerotic and Cardiac Diseases.International journal of molecular sciences · 2021Review
- Target Sestrin2 to Rescue the Damaged Organ: Mechanistic Insight into Its Function.Oxidative medicine and cellular longevity · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsAtherosclerotic disease, such as coronary artery disease (CAD), is recognized to be associated with inflammation and oxidative stress. We investigated the association between CAD and plasma levels of sestrin2 which is one of the stress-inducible antioxidant proteins.
methodsWe measured plasma sestrin2 levels in 304 patients undergoing elective coronary angiography. The severity of CAD was represented as the numbers of >50% stenotic coronary vessels and segments and the severity score.
resultsCAD was found in 175 patients, of whom 73 had 1-vessel (1-VD), 59 had 2-vessel (2-VD), and 43 had 3-vessel disease (3-VD). Plasma sestrin2 levels were significantly higher in 175 patients with CAD than in 129 without CAD (median 16.4 vs. 14.2 ng/mL,
conclusionsPlasma sestrin2 levels in patients with CAD were found to be high and to be associated with the severity of CAD. High sestrin2 levels in patients with CAD may reflect a protective response against the progression of CAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.